Richard G. Grundy

European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence

Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature

Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study

Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study

SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort—A BIOMECA Consortium Study

Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group

Recurrent ACVR1 mutations in posterior fossa ependymoma

Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas

Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors

SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study

EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY

Recurrent fusions in <i>PLAGL1</i> define a distinct subset of pediatric-type supratentorial ependymoma

Abstract B71: Molecular heterogeneity and novel oncogenic fusions in <i>RELA-</i> and <i>YAP1-</i>negative supratentorial ependymoma

EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES <i>GLI2</i> AS AN ONCOGENE OF <i>C11orf95</i> FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA

Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study

A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor

Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas

Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target

Limitations of current <i>in vitro</i> models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma

Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial

EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET

EPEN-10. ROLE OF DNA METHYLATION ANALYSIS IN RECURRENT PAEDIATRIC EPENDYMOMA

Genomic landscape of pineoblastoma.

Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease

Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification

EPND-07. MOLECULAR HETEROGENEITY AMONG PEDIATRIC POSTERIOR FOSSA EPENDYMOMA

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors

Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups

PNR-39DISTINCT GENE FUSIONS SEGREGATE SUB-CLASSES OF CNS-PNETs